Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23
Rhea-AI Filing Summary
Metagenomi Therapeutics director Reid Laurence received a grant of stock options covering 17,400 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They vest on the earlier of one year from the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Reid Laurence
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,400 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,400 shares (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Key Figures
Option grant size: 17,400 shares
Exercise price: $1.23 per share
Total derivative holdings: 17,400 options
+2 more
5 metrics
Option grant size
17,400 shares
Stock Option (Right to Buy) awarded to director
Exercise price
$1.23 per share
Strike price for the stock options
Total derivative holdings
17,400 options
Total shares underlying options after transaction
Expiration date
June 8, 2036
Option term end date
Vesting trigger
1 year or 2027 meeting
Earlier of one-year anniversary or 2027 annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.2300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common Stock""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Metagenomi Therapeutics (MGX) report for Reid Laurence?
Metagenomi Therapeutics reported that director Reid Laurence received a grant of stock options for 17,400 shares of common stock. The filing shows this as a compensation-related award, not an open-market purchase or sale of existing shares.
What is the exercise price of the new Metagenomi Therapeutics (MGX) stock options?
The granted stock options have an exercise price of $1.23 per share. This means Laurence can buy Metagenomi common stock at $1.23 once the options vest, regardless of the market price at that time, until they expire.
When do Reid Laurence’s Metagenomi (MGX) stock options vest?
The options vest upon the earlier of the one-year anniversary of the grant date or the date of Metagenomi’s 2027 annual meeting of stockholders. Vesting is conditioned on Laurence continuing to serve with the company through the applicable vesting date.
When do the newly granted Metagenomi Therapeutics (MGX) options expire?
The stock options granted to Reid Laurence expire on June 8, 2036. After that date, any unexercised portion of the 17,400-share option grant will lapse, and he will no longer be able to purchase shares under this award.
How many Metagenomi (MGX) derivative securities does Reid Laurence hold after this grant?
After this grant, Laurence holds 17,400 derivative securities in the form of stock options. The Form 4 indicates this is his total option position reported in this filing, reflecting the full size of the newly awarded grant.